Sarepta Therapeutics has announced a research and option alliance with Codiak BioSciences to design and develop engineered exosome therapeutics for neuromuscular diseases
The engineered exosome technology is believed to improve the delivery of delivering gene therapy, gene editing and RNA technologies for neuromuscular diseases without the risk of the immune response.
The focus of the companies would be to design exosomes efficient enough to deliver and functionally release select payloads, such as nucleic acids and gene therapy and gene editing constructs, in neuromuscular indications.
Under the two-year agreement, Codiak is eligible to receive up ...
